Optum study shows BLC and WLC have equivalent real-world costs for non-muscle-invasive bladder cancer, supporting adoption of blue light cystoscopy without financial penalty
Executive summary: Photocure ASA published an Optum study showing cost neutrality between blue light cystoscopy (BLC) and white light cystoscopy (WLC) in a real-world U.S. setting for non-muscle-invasive bladder cancer. The study removes a major economic objection to BLC adoption by proving superior cancer detection does not raise overall healthcare costs, potentially increasing use of the more accurate diagnostic method.
Who is involved: Photocure ASA (OSE: PHO), Optum, U.S. healthcare providers and payers managing non-muscle-invasive bladder cancer patients.
Likely next: Increased reimbursement discussions, potential updates to clinical guidelines favoring BLC, and expanded market access for Photocure’s Cysview® in the U.S.
Photocure ASA announced the publication of an Optum study demonstrating cost neutrality between blue light cystoscopy (BLC) and white light cystoscopy (WLC) in a real-world U.S. setting for non-muscle-invasive bladder cancer (NMIBC). The retrospective analysis compared healthcare resource utilization and costs, finding no significant difference between the two diagnostic approaches. This evidence addresses a key barrier to BLC adoption — perceived higher costs — by showing that improved detection does not increase overall system expenses.
Timeline
- — Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. (PR Newswire)
Analysis — what this means
Likely next events
- Photocure to present findings at AUA 2027
- Optum to consider BLC in value-based care models by Q1 2027
- CMS to review BLC coverage policies by mid-2027
Sectors affected
- Medical diagnostics
- Urology healthcare services
- Bladder cancer drug and device market
Regulatory implications
- CMS could update HCPCS coding or payment rules for BLC procedures based on cost equivalence
- NCCN guidelines may strengthen BLC recommendation based on cost-neutral efficacy
Historical parallels
- Adoption of HPV testing vs. Pap smear in cervical cancer screening (2010s) — showed cost-effectiveness despite higher upfront cost
- MRI-guided biopsy vs. TRUS in prostate cancer diagnosis (2018–2020) — demonstrated long-term savings via reduced overdiagnosis
Key entities
Sources
Open the full interactive case file on Beyond →